Skip to content
← Full study record

NCT04430894 · MORE INFO

Limitations, agreements, and source contact

KRDI in Transplant-Eligible MM · Source last updated 2026-06-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Results up to cycle 6/8 of KRDI are currently available and entered in CT.gov, including the primary endpoint and secondary endpoints that can be reported at this time. Data after the beginning of maintenance therapy (post-cycle 6 for patients who had stem cell transplants, and post-cycle 8 for patients who deferred stem cell transplant), including adverse event data, is still being collected and analyzed as of August 2023.
point Of Contact
email
Elizabeth_ODonnell@DFCI.HARVARD.EDU
organization
Dana-Farber Cancer Institute
phone
617-632-3000
title
Elizabeth K. O'Donnell, MD
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Results up to cycle 6/8 of KRDI are currently available and entered in CT.gov, including the primary endpoint and secondary endpoints that can be reported at this time. Data after the beginning of maintenance therapy (post-cycle 6 for patients who had stem cell transplants, and post-cycle 8 for patients who deferred stem cell transplant), including adverse event data, is still being collected and analyzed as of August 2023.
point Of Contact
email
Elizabeth_ODonnell@DFCI.HARVARD.EDU
organization
Dana-Farber Cancer Institute
phone
617-632-3000
title
Elizabeth K. O'Donnell, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice